PubRank

Hans von der Maase

Author PubWeight™ 62.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009 5.11
2 Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002 2.88
3 Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006 2.64
4 Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol 2011 2.32
5 European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2007 2.21
6 Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010 2.18
7 Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009 2.13
8 Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008 2.06
9 Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005 2.01
10 Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007 1.87
11 Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012 1.76
12 Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol 2002 1.61
13 Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007 1.56
14 Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies. Eur Urol 2007 1.43
15 Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 2007 1.40
16 European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2007 1.37
17 High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 2005 1.34
18 Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst 2002 1.34
19 Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 2006 1.15
20 Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother 2004 1.12
21 Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res 2006 1.09
22 Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 2006 1.04
23 Prevalence and risk of depressive symptoms 3-4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer. Breast Cancer Res Treat 2008 1.04
24 Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer. Int J Radiat Oncol Biol Phys 2004 1.03
25 Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res 2009 1.02
26 Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 2002 0.96
27 Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 2009 0.90
28 A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 2005 0.90
29 Health-related quality of life in long-term survivors of testicular cancer. J Clin Oncol 2009 0.89
30 Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res 2005 0.88
31 Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med 2013 0.85
32 Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. Acta Oncol 2004 0.84
33 A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma. Radiother Oncol 2005 0.84
34 Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer. J Cancer Res Clin Oncol 2002 0.81
35 Amplification of epidermal growth factor receptor gene in renal cell carcinoma. Eur J Cancer 2010 0.81
36 Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol 2002 0.80
37 Fear of recurrence and causal attributions in long-term survivors of testicular cancer. Psychooncology 2011 0.79
38 Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack. Clin Cancer Res 2004 0.79
39 Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy. Acta Oncol 2006 0.79
40 Screening for Y microdeletions in men with testicular cancer and undescended testis. J Assist Reprod Genet 2006 0.78
41 Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. Radiother Oncol 2004 0.78
42 Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients. Cancer Immunol Immunother 2004 0.78
43 Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma. BJU Int 2008 0.77
44 The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma. J Immunother 2007 0.77
45 Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma. Acta Oncol 2013 0.76
46 Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer. Breast Cancer Res Treat 2011 0.76
47 Serum lactate dehydrogenase isoenzyme 1 in patients with seminoma stage I followed with surveillance. Acta Oncol 2002 0.76
48 Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. Radiother Oncol 2004 0.76
49 Is a contralateral testicular biopsy in patients with unilateral germ cell testicular cancer indicated as a routine procedure? Acta Oncol 2005 0.75
50 Precursor lesions in testis and dysgenetic gonads. Hum Pathol 2006 0.75
51 [Oncologic treatment]. Ugeskr Laeger 2002 0.75
52 [Immunotherapy of cancer]. Ugeskr Laeger 2002 0.75
53 [Three cases of thrombosis of the internal jugular vein]. Ugeskr Laeger 2002 0.75
54 [Renal cancer--a new clearing report]. Ugeskr Laeger 2002 0.75
55 Radical radiotherapy for urinary bladder cancer: treatment outcomes. Expert Rev Anticancer Ther 2006 0.75
56 [Nephrectomy in metastatic renal cell carcinoma--an old myth in new clothes?]. Ugeskr Laeger 2003 0.75
57 Increased thymidylate synthase mRNA concentration in blood leukocytes following an experimental stressor. Psychother Psychosom 2002 0.75
58 Psychological stress predicts the risk of febrile episodes in cancer patients during chemotherapy. Psychother Psychosom 2009 0.75
59 [Chemotherapy as a supplement to radical treatment of patients with locally advanced bladder cancer]. Ugeskr Laeger 2005 0.75
60 [Malignant skin melanoma]. Ugeskr Laeger 2002 0.75
61 S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma. Melanoma Res 2004 0.75
62 [Testicular cancer]. Ugeskr Laeger 2002 0.75
63 [MiRNA in glioblastomas--potentials and limitations]. Ugeskr Laeger 2012 0.75
64 Allelic deletions of Rb and L-myc in urine sediments from patients with bladder tumors or carcinoma in situ. Oncol Rep 2002 0.75
65 Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma. J Invest Dermatol 2006 0.75
66 [Dendritic cell vaccination--a new therapeutic alternative for cancer patients?]. Ugeskr Laeger 2006 0.75